A Phase 2 Double-blind Randomized Placebo-controlled Multicenter Study to Evaluate Efficacy Safety and Tolerability of JBT-101 in Systemic Lupus Erythematosus

Brief description of study

This research study is being done to test the effect, safety, and tolerability of the experimental drug JBT-101 in subjects with Systemic Lupus Erythematosus (SLE). The study will examine whether JBT-101 stops inflammation and how well JBT-101 is tolerated. The study will evaluate whether JBT-101 will decrease the pain associated with active arthritis or tendonitis in Systemic Lupus Erythematosus (SLE) subjects. JBT-101 is an experimental drug being tested in subjects with SLE in this study. Corbus Pharmaceuticals, Inc. will supply this study drug. JBT-101 is manufactured entirely from chemicals and its structure is similar to the end product of a chemical in marijuana. This drug was designed to have the known anti-inflammatory properties of marijuana without the effects on brain function and mood. The drug will not have the "high feeling " of marijuana. The FDA has not approved JBT-101 for any disease


Clinical Study Identifier: s17-00084
ClinicalTrials.gov Identifier: NCT02465437


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.